WeVote
Log In

Bill

Bill

SF 163

A bill for an act relating to the definition of medical cannabidiol.

2025-2026 Regular Session Introduced by Scott Webster

Bill SF 163 expands the definition of medical cannabidiol, allowing more cannabis forms for patient use, improving access and encouraging healthcare providers to recommend treatments.

Subcommittee recommends amendment and passage.
#drugs #marijuana #medicalcare
0
WeVote Research Nonpartisan
Bill Summary · SF 163

Summary of Bill SF 163

Bill Number: SF 163
Title: A bill for an act relating to the definition of medical cannabidiol.
Status: Subcommittee recommends amendment and passage.
Introduced: January 29, 2025
Classification: Bill
Subject: Drugs, Marijuana, Medical Care

Purpose and Intent

Bill SF 163 aims to amend the existing definition of "medical cannabidiol" within the state's medical cannabis program. The intent is to clarify and expand the types of cannabis products that qualify as medical cannabidiol, thereby enhancing access for patients who may benefit from these treatments.

Key Provisions

The bill proposes the following changes to Section 124E.2, subsection 10 of the Code 2025:

  • Expanded Definition: The term "medical cannabidiol" will now encompass any species of the cannabis plant or any mixture or preparation thereof, including whole plant extracts and resins.

  • Forms of Delivery: The bill specifies that medical cannabidiol can be delivered in various forms, categorized as follows:

    • Oral Forms:
    • Tablets
    • Capsules
    • Liquids
    • Tinctures
    • Sublingual forms
    • Topical Forms:
    • Gels
    • Ointments, creams, or lotions
    • Transdermal patches
    • Inhaled Forms:
    • Nebulizable inhaled forms
    • Vaporizable dried raw cannabis
    • Other vaporizable forms of cannabis

Impact

The amendments proposed in SF 163 are expected to:

  • Broaden Access: By including a wider variety of cannabis forms, the bill aims to improve access for patients who may require different methods of administration for effective treatment.
  • Support Medical Use: The clarification of the definition may encourage more healthcare providers to recommend medical cannabis as a treatment option, potentially benefiting patients with various medical conditions.

Legislative Timeline

  • January 29, 2025: Bill introduced and referred to the Health and Human Services Committee.
  • February 4, 2025: Subcommittee formed, consisting of members Klimesh, Campbell, and Trone Garriott.
  • February 19, 2025: Subcommittee meeting scheduled for February 20, 2025, at 2:00 PM in the Senate Lounge.
  • February 20, 2025: Subcommittee recommends amendment and passage of the bill.

Conclusion

Bill SF 163 represents a significant step towards enhancing the medical cannabis program by providing a clearer and more inclusive definition of medical cannabidiol. If passed, it could lead to improved patient care and access to necessary treatments.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.